Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
Sponsor: Fudan University
Summary
This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer. The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion criteria were screened according to the inclusion and exclusion criteria. Demographic information, clinical characteristics, tumor treatment history, medication regimen, adverse reactions, molecular test results, survival follow-up results and other data were collected. The prospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 Chinese hospitals from January 2024 to April 2027 were enrolled.
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
800
Start Date
2020-01-01
Completion Date
2028-12-31
Last Updated
2025-08-14
Healthy Volunteers
No
Interventions
dabrafenib plus trametinib with or without PD-1 antibody
advanced thyroid cancer patients who harbor BRAF V600E mutation
entrectinib or larotrectinib with or without anti-PD-1 antibdoy
advanced thyroid cancer patients who harbor NTRK mutation
pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.
anlotinib or anlotinib plus anti-PD-1 antibody
For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown
lenvatinib plus anti-PD-1 antibody
Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation
Other Targets: precise treatment based on the target
Advanced thyroid cancer patients who had other treatment targets not included above
Locations (8)
Fujian Cancer Hospital
Fuzhou, Fujian, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
Caixia Liu
Hohhot, Inner Mongolia, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Shanxi Cancer Hospital
Shanxi, Taiyuan, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Peking union medical college hospital
Beijing, China